Chimeric peptides against htlv-1
OwnerMona Kabiri, Mohsen Tafaghodi Piadeh Gheibi +1inventors
InventorsMona Kabiri, Mohsen Tafaghodi Piadeh Gheibi, Mojtaba Sankian
Life of this patent
Estimating the term…
Abstract
A method of immunizing against HTLV-1 is disclosed. The method may include preparing a DNA sequence corresponding to a chimeric peptide which may have immunogenic epitopes of HTLV-1. These epitopes can include a Tax epitope, a gp21 epitope, a gp46 epitope, and/or a gag epitope. The method also includes production of the chimeric peptide using the DNA sequence and purifying the produced chimeric peptide. The purified chimeric peptide can be employed for immunization against HTLV-1.
Claims20
A method for immunizing against human T-lymphotropic virus type 1 (HTLV-1), the method comprising:
- preparing a DNA sequence, wherein the DNA sequence encodes a chimeric peptide with immunogenic epitopes including a Tax epitope, a gp21 epitope, a gp46 epitope, and a gag epitope;
- producing the chimeric peptide using the DNA sequence;
- purifying the produced chimeric peptide;
- and
- immunizing against HTLV-1 using the purified chimeric peptide.
A chimeric peptide for inducing an immune response against human T-lymphotropic virus-1 (HTLV-1), the chimeric peptide comprising:
- a plurality of immunogenic epitopes of HTLV-1 including:
- a Tax epitope,
- a gp21 epitope,
- a gp46 epitope, and
- a gag epitope,
- wherein the immunogenic epitopes are connected together sequentially with a linker.
Dependencies are inferred from the claim text.